Potential clinical treatment of colitis with cardiotrophin-1

摘要: In a recent issue of Clinical Science, Prieto-Vicente et al. [Clin. Sci. (2018) 132, 985-1001] have smartly demonstrated potential new use cardiotrophin-1 (CT-1) to treat and palliate an inflammatory bowel disease such as ulcerative colitis. that work, authors report in colitic mice, administration exogenous recombinant CT-1 (rCT-1) promotes lower colon damage activity index, reducing systemic levels tumor necrosis factor α (TNF-α) also diminishing TNF-α expression together with the reduction other common inflammation markers. Besides, vivo rCT-1 induces activation several molecular pathways, including nuclear κ-light-chain-enhancer activated B cells (NF-κB) signal transducer activator transcription (STAT)-3, abolishes bacterial translocation from intestine organs, mesenteric ganglia, lungs, spleen. Additionally, these results were nicely corroborated depleted mice; which colitis severity greater compared wild-type counterparts. All together, suggested could be promising therapeutic approach for treating disease, particularly However, further studies are required determine its major mechanisms action efficacy human diseases.